Results 71 to 80 of about 160,497 (241)
PHARMACOLOGICAL THERAPY OF HEPATOCELLULAR CANCER PRACTICAL ISSUES AND SOLUTIONS
Медицинский совет, 2017 Pharmaceutical therapy of hepatocellular carcinoma represents a major clinical issue of debate in modern oncology. Until now, Sorafenib remains the only option for the management of locally advanced and metastatic hepatocellular carcinomas, which ...
V. V. Breder +2 more
doaj +1 more source
Advanced Science, EarlyView.Glutamine deprivation triggers transient DNA damage yet activates adaptive repair in hepatocellular carcinoma cells. We identify TRIB3 as a stress‐induced nuclear scaffold that associates with DDX5 and G‐quadruplex DNA atBRCA1 andRAD51AP1 promoters. TRIB3 loss increases G4 accumulation, suppresses HR gene transcription, elevates γ‐H2A.X, and sensitizes
Qiang Ji +10 more
wiley +1 more source
Hepatology, EarlyView., 2022 KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou +15 more
wiley +1 more source
Cancer Management and Research, 2020 Bashan Zhang, Fei Li, Zinian Zhu, Aijiao Ding, Jintong Luo Department of Clinical Laboratory, Affiliated Dongguan People’s Hospital, Southern Medical University of Dongguan, Dongguan City, Guangdong Province, People’s Republic of ...
Zhang B, Li F, Zhu Z, Ding A, Luo J
doaj
Advanced Science, EarlyView.This study developed an eEF2K‐targeting PROTAC, A6, that efficiently degrades eEF2K in TNBC cells, inhibiting tumor growth in vitro and in vivo. To enhance tumor‐specific delivery, we engineered A6@ZIF‐8, a pH‐sensitive nanocarrier, which improved drug accumulation at tumor sites, offering a promising therapeutic strategy for TNBC through targeted ...
Shijun Cao +10 more
wiley +1 more source
Relationship between NAFLD and coronary artery disease: A Mendelian randomization study
Hepatology, EarlyView., 2022 Abstract Background and Aims There is an ongoing debate on whether NAFLD is an active contributor or an innocent bystander in the pathogenesis of coronary artery disease (CAD). The aim of the present study was to assess the causal relationship between NAFLD and CAD.
Zhewen Ren +4 more
wiley +1 more source
Journal of Hepatocellular Carcinoma, 2023 Zhilu Yao,1,2,* Ning Liu,3,* Hui Lin,1 Yingqun Zhou2,4 1Department of Gastroenterology, Jingan District Zhabei Central Hospital, Shanghai, 200072, People’s Republic of China; 2Clinical Medical College of Shanghai Tenth People’s Hospital, Nanjing ...
Yao Z, Liu N, Lin H, Zhou Y
doaj
Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression
Advanced Science, EarlyView.This study uncovers a new oncogenic mechanism in melanoma. The transcription factor PATZ1 competes with the architectural protein CTCF for DNA binding, thereby disrupting a specific chromatin loop and silencing the tumor suppressor ZBTB20. This event unleashes the pro‐tumorigenic PMEPA1‐p38‐STAT1 signaling axis, promoting cancer progression.
Chaowei Deng +8 more
wiley +1 more source
NAFLD‐related hepatocellular carcinoma: The growing challenge
Hepatology, EarlyView., 2022 Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah +2 more
wiley +1 more source
scRNA-Seq Analysis Revealed CAFs Regulating HCC Cells via PTN Signaling
Journal of Hepatocellular CarcinomaWenxian Lin,1– 4 Lizhu Tang,1,2,5 Chenyi Zhuo,1 Xiuli Mao,1– 4 Jiajia Shen,6 Shaoang Huang,3 Shangyang Li,3,7 Yujuan Qin,3,4 Ju Liao,2,3 Yuhong Chen,8 Xiamin Zhang,3,4 Yuting Li,9 Jian Song,4 Lingzhang Meng,4 Xiaofeng Dong,10 Yueyong Li2 1Key Laboratory ...
Lin W +15 more
doaj